Recursion Pharmaceuticals, Inc. RXRX Total debt

Total debt at other companies

SchrodingerSDGR

$107.98M-5.5%

Absci CorporationABSI

$4M-37.2%

AbCellera Biologics Inc.ABCL

$135.62M-4.5%

Relay Therapeutics, Inc.RLAY

$30.66M-10.3%

Septerna, Inc.SEPN

$23.09M-7.7%

XencorXNCR

$170.11M-20.1%

FAQ

What is Recursion Pharmaceuticals, Inc.'s total debt?

Recursion Pharmaceuticals, Inc. (RXRX) reported total debt of $80.54M in Q2 2026.

How has Recursion Pharmaceuticals, Inc.'s total debt changed year-over-year?

Recursion Pharmaceuticals, Inc.'s total debt decreased by 27.2% year-over-year, from $110.68M to $80.54M.

What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total debt?

Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total debt has grown at a 53.2% compound annual growth rate (CAGR), from $11.41M to $96.3M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.